New patent for a novel diagnostic test to
detect anti-microbial resistance filed, after successful completion of
development and initial testing
Oxford Vacmedix (OVM), the UK clinical
stage biopharma company, focused on the development of a new generation of
cancer vaccines, announced today that project work to develop a novel
diagnostic test for anti-microbial resistance, funded by Innovate UK, has been
filed as a patent in the UK.
